KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Halozyme Therapeutics (HALO) over the last 13 years, with Q3 2025 value amounting to $71.8 million.

  • Halozyme Therapeutics' Other Non-Current Liabilities rose 7769.39% to $71.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.8 million, marking a year-over-year increase of 7769.39%. This contributed to the annual value of $54.8 million for FY2024, which is 4516.97% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported Other Non-Current Liabilities of $71.8 million as of Q3 2025, which was up 7769.39% from $77.8 million recorded in Q2 2025.
  • Over the past 5 years, Halozyme Therapeutics' Other Non-Current Liabilities peaked at $130.0 million during Q2 2022, and registered a low of $171000.0 during Q1 2022.
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $31.2 million (2024), whereas its average is $41.5 million.
  • As far as peak fluctuations go, Halozyme Therapeutics' Other Non-Current Liabilities plummeted by 9391.24% in 2022, and later surged by 1719415.2% in 2023.
  • Halozyme Therapeutics' Other Non-Current Liabilities (Quarter) stood at $544000.0 in 2021, then skyrocketed by 5908.46% to $32.7 million in 2022, then increased by 15.4% to $37.7 million in 2023, then surged by 45.17% to $54.8 million in 2024, then surged by 31.12% to $71.8 million in 2025.
  • Its Other Non-Current Liabilities was $71.8 million in Q3 2025, compared to $77.8 million in Q2 2025 and $56.4 million in Q1 2025.